Cargando…

bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy

Detalles Bibliográficos
Autores principales: Xu, Gehan, Cui, Liang, Li, Jin, Wang, Quanren, Li, Pansong, Xia, Xuefeng, Yi, Xin, Guan, Quanlin, Xu, Jianming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574487/
https://www.ncbi.nlm.nih.gov/pubmed/36245284
http://dx.doi.org/10.1002/ctm2.1086
_version_ 1784811113893855232
author Xu, Gehan
Cui, Liang
Li, Jin
Wang, Quanren
Li, Pansong
Xia, Xuefeng
Yi, Xin
Guan, Quanlin
Xu, Jianming
author_facet Xu, Gehan
Cui, Liang
Li, Jin
Wang, Quanren
Li, Pansong
Xia, Xuefeng
Yi, Xin
Guan, Quanlin
Xu, Jianming
author_sort Xu, Gehan
collection PubMed
description
format Online
Article
Text
id pubmed-9574487
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95744872022-10-17 bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy Xu, Gehan Cui, Liang Li, Jin Wang, Quanren Li, Pansong Xia, Xuefeng Yi, Xin Guan, Quanlin Xu, Jianming Clin Transl Med Letter to the Editor John Wiley and Sons Inc. 2022-10-17 /pmc/articles/PMC9574487/ /pubmed/36245284 http://dx.doi.org/10.1002/ctm2.1086 Text en © 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to the Editor
Xu, Gehan
Cui, Liang
Li, Jin
Wang, Quanren
Li, Pansong
Xia, Xuefeng
Yi, Xin
Guan, Quanlin
Xu, Jianming
bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy
title bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy
title_full bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy
title_fullStr bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy
title_full_unstemmed bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy
title_short bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy
title_sort bmsaf is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574487/
https://www.ncbi.nlm.nih.gov/pubmed/36245284
http://dx.doi.org/10.1002/ctm2.1086
work_keys_str_mv AT xugehan bmsafisaprognosticpredictorforadvancedhepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorcamrelizumabandantiangiogenicagentapatinibcombinationtherapy
AT cuiliang bmsafisaprognosticpredictorforadvancedhepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorcamrelizumabandantiangiogenicagentapatinibcombinationtherapy
AT lijin bmsafisaprognosticpredictorforadvancedhepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorcamrelizumabandantiangiogenicagentapatinibcombinationtherapy
AT wangquanren bmsafisaprognosticpredictorforadvancedhepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorcamrelizumabandantiangiogenicagentapatinibcombinationtherapy
AT lipansong bmsafisaprognosticpredictorforadvancedhepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorcamrelizumabandantiangiogenicagentapatinibcombinationtherapy
AT xiaxuefeng bmsafisaprognosticpredictorforadvancedhepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorcamrelizumabandantiangiogenicagentapatinibcombinationtherapy
AT yixin bmsafisaprognosticpredictorforadvancedhepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorcamrelizumabandantiangiogenicagentapatinibcombinationtherapy
AT guanquanlin bmsafisaprognosticpredictorforadvancedhepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorcamrelizumabandantiangiogenicagentapatinibcombinationtherapy
AT xujianming bmsafisaprognosticpredictorforadvancedhepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorcamrelizumabandantiangiogenicagentapatinibcombinationtherapy